Browse BMI1

Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF16207 RAWUL domain RING finger- and WD40-associated ubiquitin-like
Function

Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:15386022, PubMed:16359901, PubMed:26151332, PubMed:16714294, PubMed:21772249, PubMed:25355358, PubMed:27827373). The complex composed of RNF2, UB2D3 and BMI1 binds nucleosomes, and has activity only with nucleosomal histone H2A (PubMed:21772249, PubMed:25355358). In the PRC1-like complex, regulates the E3 ubiquitin-protein ligase activity of RNF2/RING2 (PubMed:15386022, PubMed:26151332, PubMed:21772249).

> Gene Ontology
 
Biological Process GO:0003002 regionalization
GO:0007379 segment specification
GO:0007389 pattern specification process
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0035282 segmentation
GO:0040029 regulation of gene expression, epigenetic
GO:0045814 negative regulation of gene expression, epigenetic
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051443 positive regulation of ubiquitin-protein transferase activity
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
Molecular Function GO:0003682 chromatin binding
GO:0071535 RING-like zinc finger domain binding
GO:1990841 promoter-specific chromatin binding
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0000152 nuclear ubiquitin ligase complex
GO:0031519 PcG protein complex
GO:0035102 PRC1 complex
> KEGG and Reactome Pathway
 
KEGG hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-392499: Metabolism of proteins
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3108214: SUMOylation of DNA damage response and repair proteins
R-HSA-4570464: SUMOylation of RNA binding proteins
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BMI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BMI1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29626519breast carcinomaInhibit immunityThese DEGs were enriched with reductions in immunological processes, indicating a role of BMI1 in downregulation of the immune surveillance.
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BMI1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BMI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.360.437
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.2310.557
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.260.845
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1260.667
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0950.957
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1620.944
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.160.568
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2230.696
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0270.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0670.959
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.680.725
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0970.256
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BMI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BMI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BMI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BMI1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BMI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BMI1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BMI1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBMI1
NameBMI1 proto-oncogene, polycomb ring finger
Aliases RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BMI1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.